A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
← catalyst calendarNCT06388200 · readout in 177 d
Sponsored by Ocugen (industry) · OCGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
140actual
Sites
17
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-18 | actual | When the study began enrolling |
| Primary completion | 2027-02-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-12 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Retinitis Pigmentosa
Intervention
- Genetic: Sub-Retinal Administration of OCU400-301
Primary outcome
what the primary-completion date above is the date OFChange in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control
measured 52 weeks
Permalink · OCGN's whole pipeline · Catalyst calendar · Every registered study · What changed